Study Summary
To observe the safety, tolerability and initial effectiveness of gene modified T cell therapy in patients with malignant tumors in First Affiliated Hospital of Zhengzhou University, China.
Want to learn more about this trial?
Request More InfoInterventions
CAR-T cell reinfusionBIOLOGICAL
Subjects were identified according to their benefit from the first treatment and target expression Whether to accept multiple returns; CAR-T cell reinfusion dose was 1\~10×106 cells/kg, and the reinfusion dose could be adjusted according to the tolerance of the subjects Usually intravenous infusion, but also according to the need for local interventional treatment or injection treatment
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Zhengzhou University First Affiliated Hospital | Zhengzhou | Henan | China |